ImmunoGen gets FDA breakthrough therapy status for IMGN632 to treat relapsed or refractory BPDCN

This article was originally published here

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which

The post ImmunoGen gets FDA breakthrough therapy status for IMGN632 to treat relapsed or refractory BPDCN appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply